Tingting Li1, Xue Shen1, Xiaoxue Xie1, Zhongyuan Chen1, Shun Li1,2, Xiang Qin1,2, Hong Yang1,2, Chunhui Wu1,2, Yiyao Liu1,2. 1. Department of Biophysics, School of Life Science & Technology, University of Electronic Science and Technology of China, Chengdu 610054, Sichuan, PR China. 2. Center for Information in Biology, University of Electronic Science & Technology of China, Chengdu 610054, Sichuan, PR China.
Abstract
AIM: To enhance synergistic therapeutic effects in breast cancer therapy. Here, we used hollow mesoporous silica nanoparticles as a biocompatible carrier to coload chemotherapy drugs Irinotecan and near-infrared IR-820 dye, which enhanced antitumor efficacy by combining chemotherapy and phototherapy. METHODS: The successful synthesis of hollow mesoporous silica nanoparticles/Irinotecan/IR820 (HMII) nanocomplex was confirmed by Fourier transform infrared spectroscopy and Fluorescence spectra. The photothermal conversion efficiency and antitumor efficiency in murine breast cancer cells (EMT-6) bearing mice were further evaluated. RESULTS: The results demonstrated that HMII enhanced the delivery of Irinotecan and IR-820 into EMT-6 cells. HMII generated a high temperature upon a near-infrared laser irradiation (808 nm), and showed higher therapeutic efficacy in EMT-6-bearing mice compared with either HMII without laser or free drug with a laser. CONCLUSION: HMII is a desired drug codelivery system to efficiently inhibit the growth of breast cancer.
AIM: To enhance synergistic therapeutic effects in breast cancer therapy. Here, we used hollow mesoporous silica nanoparticles as a biocompatible carrier to coload chemotherapy drugs Irinotecan and near-infrared IR-820 dye, which enhanced antitumor efficacy by combining chemotherapy and phototherapy. METHODS: The successful synthesis of hollow mesoporous silica nanoparticles/Irinotecan/IR820 (HMII) nanocomplex was confirmed by Fourier transform infrared spectroscopy and Fluorescence spectra. The photothermal conversion efficiency and antitumor efficiency in murinebreast cancer cells (EMT-6) bearing mice were further evaluated. RESULTS: The results demonstrated that HMII enhanced the delivery of Irinotecan and IR-820 into EMT-6 cells. HMII generated a high temperature upon a near-infrared laser irradiation (808 nm), and showed higher therapeutic efficacy in EMT-6-bearing mice compared with either HMII without laser or free drug with a laser. CONCLUSION: HMII is a desired drug codelivery system to efficiently inhibit the growth of breast cancer.